10月11日晚,君实生物发布公告称,公司旗下昂戈瑞西单抗注射液获国家药品监督管理局批准上市,昂戈瑞西单抗注射液用于治疗原发性高胆固醇血症(非家族性)和混合型血脂异常成人患者。就在国庆节前,国家药品监督管理局还批准了康方生物自主研发的1类新药伊努西单抗的上市许可申请,用于治疗原发性高胆固醇血症和混合型高脂血症,以及杂合子型家族性高胆固醇血症。PCSK9抑制剂如今已成为经典他汀类药物的有力补充,是一种...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.